Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

June 1, 2018

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Clostridium Difficile InfectionHematologic DiseasesBone Marrow TransplantOncologic Disorders
Interventions
DRUG

Vancomycin Oral Capsule

We have chosen oral vancomycin capsules as it is currently a standard of care for Clostridium difficile infections, is poorly absorbed by the intestines, and is easier to blind compared to oral vancomycin solution.

DRUG

Placebo Oral Capsule

A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD\&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.

Trial Locations (1)

53226

Froedtert and the Medical College of Wisconsin, Milwaukee

All Listed Sponsors
lead

Medical College of Wisconsin

OTHER

NCT03030248 - Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients | Biotech Hunter | Biotech Hunter